18th Nov 2020 20:23
PureTech Health PLC - Boston-based biotherapeutics company - Announces completion of Phase 1 multiple ascending dose and food effect study for LYT-100. The study demonstrated favourable proof-of-concept for LYT-100's tolerability and pharmacokinetic profile, which will also enable twice-a-day dosing of LYT-100 in future studies.
"The strong results from this Phase one readout reinforce our view that LYT-100 has the potential to offer a tolerability and bioavailability profile that could be highly differentiated at the same exposure levels as pirfenidone," notes Daphne Zohar, co-founder and chief executive officer of PureTech.
Current stock price: 296.50 pence
Year-to-date change: down 7.3%
By Arvind Bhunjun; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
PureTech